Cannabidiol | CAS#13956-29-1

MedKoo Cat#: 319869 | Name: Cannabidiol

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Cannabidiol (CBD) is a non-psychoactive compound derived from cannabis. It exerts its effects primarily by modulating the endocannabinoid system (ECS). While CBD does not directly bind to cannabinoid receptors (CB1 and CB2) like THC, it influences their activity indirectly. Key mechanisms include: (a) Inhibition of Enzymes: CBD inhibits fatty acid amide hydrolase (FAAH), an enzyme that breaks down anandamide, increasing its levels and enhancing ECS activity.(b) Receptor Modulation: CBD interacts with non-cannabinoid receptors such as serotonin (5-HT1A) and vanilloid (TRPV1) receptors, contributing to its anxiolytic, anti-inflammatory, and pain-relieving effects. (c) Neuroprotection: CBD reduces oxidative stress and inflammation, offering potential neuroprotective effects. These mechanisms underlie CBD's potential therapeutic applications for conditions like anxiety, epilepsy, inflammation, and chronic pain.

Chemical Structure

Cannabidiol

CAS#13956-29-1

Theoretical Analysis

MedKoo Cat#: 319869

Name: Cannabidiol

CAS#: 13956-29-1

Chemical Formula: C21H30O2

Exact Mass: 314.2246

Molecular Weight: 314.47

Elemental Analysis: C, 80.21; H, 9.62; O, 10.18

Price and Availability

Size	Price	Availability	Quantity
100mg	USD 750.00	2 Weeks
1g	USD 3,650.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

Cannabidiol, (-)-Cannabidiol; (-)-trans-Cannabidiol; CBD; (-)-CBD; GWP42003-P; GWP-42003-P; GWP 42003-P; ZYN002; ZYN-002; ZYN 002; delta1(2)-trans-Cannabidiol; Epidioloex

IUPAC/Chemical Name

2-[1R-3-methyl-6R-(1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-1,3-benzenediol

InChi Key

QHMBSVQNZZTUGM-ZWKOTPCHSA-N

InChi Code

InChI=1S/C21H30O2/c1-5-6-7-8-16-12-19(22)21(20(23)13-16)18-11-15(4)9-10-17(18)14(2)3/h11-13,17-18,22-23H,2,5-10H2,1,3-4H3/t17-,18+/m0/s1

SMILES Code

OC1=CC(CCCCC)=CC(O)=C1[C@@H]2C=C(C)CC[C@H]2C(C)=C

Appearance

Solid

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO, not in water

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 314.47 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Kis B, Ifrim FC, Buda V, Avram S, Pavel IZ, Antal D, Paunescu V, Dehelean CA, Ardelean F, Diaconeasa Z, Soica C, Danciu C. Cannabidiol-from Plant to Human Body: A Promising Bioactive Molecule with Multi-Target Effects in Cancer. Int J Mol Sci. 2019 Nov 25;20(23). pii: E5905. doi: 10.3390/ijms20235905. Review. PubMed PMID: 31775230. 2: Davies C, Bhattacharyya S. Cannabidiol as a potential treatment for psychosis. Ther Adv Psychopharmacol. 2019 Nov 8;9:2045125319881916. doi: 10.1177/2045125319881916. eCollection 2019. Review. PubMed PMID: 31741731; PubMed Central PMCID: PMC6843725. 3: de Carvalho Reis R, Almeida KJ, da Silva Lopes L, de Melo Mendes CM, Bor-Seng-Shu E. Efficacy and adverse event profile of cannabidiol and medicinal cannabis for treatment-resistant epilepsy: Systematic review and meta-analysis. Epilepsy Behav. 2019 Nov 12;102:106635. doi: 10.1016/j.yebeh.2019.106635. [Epub ahead of print] Review. PubMed PMID: 31731110. 4: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Available from http://www.ncbi.nlm.nih.gov/books/NBK548890/ PubMed PMID: 31644197. 5: Junior NCF, Dos-Santos-Pereira M, Guimarães FS, Del Bel E. Cannabidiol and Cannabinoid Compounds as Potential Strategies for Treating Parkinson's Disease and L-DOPA-Induced Dyskinesia. Neurotox Res. 2019 Oct 22. doi: 10.1007/s12640-019-00109-8. [Epub ahead of print] Review. PubMed PMID: 31637586. 6: Freeman AM, Petrilli K, Lees R, Hindocha C, Mokrysz C, Curran HV, Saunders R, Freeman TP. How does cannabidiol (CBD) influence the acute effects of delta-9-tetrahydrocannabinol (THC) in humans? A systematic review. Neurosci Biobehav Rev. 2019 Dec;107:696-712. doi: 10.1016/j.neubiorev.2019.09.036. Epub 2019 Sep 30. Review. PubMed PMID: 31580839. 7: R Mokoena D, P George B, Abrahamse H. Enhancing Breast Cancer Treatment Using a Combination of Cannabidiol and Gold Nanoparticles for Photodynamic Therapy. Int J Mol Sci. 2019 Sep 26;20(19). pii: E4771. doi: 10.3390/ijms20194771. Review. PubMed PMID: 31561450; PubMed Central PMCID: PMC6801525. 8: Calapai G, Mannucci C, Chinou I, Cardia L, Calapai F, Sorbara EE, Firenzuoli B, Ricca V, Gensini GF, Firenzuoli F. Preclinical and Clinical Evidence Supporting Use of Cannabidiol in Psychiatry. Evid Based Complement Alternat Med. 2019 Aug 29;2019:2509129. doi: 10.1155/2019/2509129. eCollection 2019. Review. PubMed PMID: 31558911; PubMed Central PMCID: PMC6735178. 9: Jung B, Lee JK, Kim J, Kang EK, Han SY, Lee HY, Choi IS. Synthetic Strategies for (-)-Cannabidiol and Its Structural Analogs. Chem Asian J. 2019 Nov 4;14(21):3749-3762. doi: 10.1002/asia.201901179. Epub 2019 Oct 8. Review. PubMed PMID: 31529613. 10: VanDolah HJ, Bauer BA, Mauck KF. Clinicians' Guide to Cannabidiol and Hemp Oils. Mayo Clin Proc. 2019 Sep;94(9):1840-1851. doi: 10.1016/j.mayocp.2019.01.003. Epub 2019 Aug 22. Review. PubMed PMID: 31447137. 11: Bonaccorso S, Ricciardi A, Zangani C, Chiappini S, Schifano F. Cannabidiol (CBD) use in psychiatric disorders: A systematic review. Neurotoxicology. 2019 Sep;74:282-298. doi: 10.1016/j.neuro.2019.08.002. Epub 2019 Aug 11. Review. PubMed PMID: 31412258. 12: Franco V, Perucca E. Pharmacological and Therapeutic Properties of Cannabidiol for Epilepsy. Drugs. 2019 Sep;79(13):1435-1454. doi: 10.1007/s40265-019-01171-4. Review. PubMed PMID: 31372958. 13: Batalla A, Janssen H, Gangadin SS, Bossong MG. The Potential of Cannabidiol as a Treatment for Psychosis and Addiction: Who Benefits Most? A Systematic Review. J Clin Med. 2019 Jul 19;8(7). pii: E1058. doi: 10.3390/jcm8071058. Review. PubMed PMID: 31330972; PubMed Central PMCID: PMC6678854. 14: Calpe-López C, García-Pardo MP, Aguilar MA. Cannabidiol Treatment Might Promote Resilience to Cocaine and Methamphetamine Use Disorders: A Review of Possible Mechanisms. Molecules. 2019 Jul 16;24(14). pii: E2583. doi: 10.3390/molecules24142583. Review. PubMed PMID: 31315244; PubMed Central PMCID: PMC6680550. 15: Carvalho RK, Andersen ML, Mazaro-Costa R. The effects of cannabidiol on male reproductive system: A literature review. J Appl Toxicol. 2019 Jul 17. doi: 10.1002/jat.3831. [Epub ahead of print] Review. PubMed PMID: 31313338. 16: Taylor Levine M, Gao J, Satyanarayanan SK, Berman S, Rogers JT, Mischoulon D. S-adenosyl-l-methionine (SAMe), cannabidiol (CBD), and kratom in psychiatric disorders: Clinical and mechanistic considerations. Brain Behav Immun. 2019 Jul 10. pii: S0889-1591(19)30278-8. doi: 10.1016/j.bbi.2019.07.013. [Epub ahead of print] Review. PubMed PMID: 31301401. 17: Brown JD, Winterstein AG. Potential Adverse Drug Events and Drug-Drug Interactions with Medical and Consumer Cannabidiol (CBD) Use. J Clin Med. 2019 Jul 8;8(7). pii: E989. doi: 10.3390/jcm8070989. Review. PubMed PMID: 31288397; PubMed Central PMCID: PMC6678684. 18: Millar SA, Stone NL, Bellman ZD, Yates AS, England TJ, O'Sullivan SE. A systematic review of cannabidiol dosing in clinical populations. Br J Clin Pharmacol. 2019 Sep;85(9):1888-1900. doi: 10.1111/bcp.14038. Epub 2019 Jul 19. Review. PubMed PMID: 31222854; PubMed Central PMCID: PMC6710502. 19: De Ternay J, Naassila M, Nourredine M, Louvet A, Bailly F, Sescousse G, Maurage P, Cottencin O, Carrieri PM, Rolland B. Therapeutic Prospects of Cannabidiol for Alcohol Use Disorder and Alcohol-Related Damages on the Liver and the Brain. Front Pharmacol. 2019 May 31;10:627. doi: 10.3389/fphar.2019.00627. eCollection 2019. Review. PubMed PMID: 31214036; PubMed Central PMCID: PMC6554654. 20: Samanta D. Cannabidiol: A Review of Clinical Efficacy and Safety in Epilepsy. Pediatr Neurol. 2019 Jul;96:24-29. doi: 10.1016/j.pediatrneurol.2019.03.014. Epub 2019 Mar 22. Review. PubMed PMID: 31053391.